-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Downgrades Crinetics Pharmaceuticals to In-Line, Lowers Price Target to $85

Benzinga·07/08/2026 09:42:08
Listen to the news
Evercore ISI Group analyst Gavin Clark-Gartner downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Outperform to In-Line and lowers the price target from $88 to $85.